Evaluation of Isoniazid-Induced Toxicity in a Murine Model of Metabolic Syndrome
DOI:
https://doi.org/10.65761/jbs.2026.67Keywords:
Isoniazid; Metabolic syndrome; Hepatotoxicity; Nephrotoxicity; Swiss albino miceAbstract
Background: Isoniazid (INH) is an essential antitubercular drug, but its use may cause adverse effects, particularly hepatotoxicity. Metabolic syndrome may increase susceptibility to drug-induced organ injury through oxidative stress, inflammation, and metabolic dysfunction.
This study evaluated the toxic effects of different doses of INH in mice with experimentally induced metabolic syndrome.
Methods: Fifty adult male Swiss albino mice were randomly allocated into six groups. Metabolic syndrome was induced using monosodium glutamate (MSG; 4.16 mg/g) for 41.6 days, followed by INH administration at 26, 52, or 104 mg/kg for 10.4 days. Body weight, food and water intake, fasting blood glucose, Mouse Grimace Scale, general toxicity signs, and survival were monitored. Serum ALT, AST, creatinine, and BUN were measured to assess hepatic and renal function.
Results: INH produced dose-dependent toxicity, with the greatest effects observed in the MSG+104 mg/kg INH group. This group showed increased fasting glucose, behavioral distress, ALT, AST, creatinine, and BUN, accompanied by reduced food intake and survival. Moderate changes were observed at the intermediate INH dose.
Conclusion: INH toxicity was enhanced in mice with metabolic syndrome, particularly at higher doses, indicating increased hepatic, renal, metabolic, and systemic vulnerability.
References
1. Islam MS, Wei P, Suzauddula M, Nime I, Feroz F, Acharjee M, Pan F. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Molecular Medicine. 2024 Dec 27;30(1):279. https://doi.org/10.1186/s10020-024-01019-y
2. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of oxidative stress in metabolic syndrome. International journal of molecular sciences. 2023 Apr 26;24(9):7898. https://doi.org/10.3390/ijms24097898
3. Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic syndrome pathophysiology and predisposing factors. International journal of sports medicine. 2021 Mar;42(03):199-214. DOI: 10.1055/a-1263-0898
4. Stefan N, Schulze MB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. The lancet Diabetes & endocrinology. 2023 Jun 1;11(6):426-40. https://doi.org/10.1016/S2213-8587(23)00086-4
5. Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, Powell-Wiley TM, Després JP. Metabolic syndrome. Nature Reviews Disease Primers. 2024 Oct 17;10(1):77. https://doi.org/10.1038/s41572-024-00563-5
6. Angelico F, Baratta F, Coronati M, Ferro D, Del Ben M. Diet and metabolic syndrome: a narrative review. Internal and emergency medicine. 2023 Jun;18(4):1007-17. https://doi.org/10.1007/s11739-023-03226-7
7. Ferrari CK. Epidemiology of metabolic syndrome: global scenario. InMetabolic Syndrome 2024 Jan 1 (pp. 59-71). Academic Press. https://doi.org/10.1016/B978-0-323-85732-1.00038-4
8. Castro-Barquero S, Ruiz-León AM, Sierra-Pérez M, Estruch R, Casas R. Dietary strategies for metabolic syndrome: a comprehensive review. Nutrients. 2020 Sep 29;12(10):2983. https://doi.org/10.3390/nu12102983
9. Wronka M, Krzemińska J, Młynarska E, Rysz J, Franczyk B. The influence of lifestyle and treatment on oxidative stress and inflammation in diabetes. International journal of molecular sciences. 2022 Dec 12;23(24):15743. https://doi.org/10.3390/ijms232415743
10. Fakih W, Zeitoun R, AlZaim I, Eid AH, Kobeissy F, Abd‐Elrahman KS, El‐Yazbi AF. Early metabolic impairment as a contributor to neurodegenerative disease: Mechanisms and potential pharmacological intervention. Obesity. 2022 May;30(5):982-93. https://doi.org/10.1002/oby.23400
11. Niewiadomska, J., Gajek-Marecka, A., Gajek, J., & Noszczyk-Nowak, A. (2022). Biological potential of polyphenols in the context of metabolic syndrome: an analysis of studies on animal models. Biology, 11(4), 559. https://doi.org/10.3390/biology11040559
12. Tran V, De Silva TM, Sobey CG, Lim K, Drummond GR, Vinh A, Jelinic M. The vascular consequences of metabolic syndrome: rodent models, endothelial dysfunction, and current therapies. Frontiers in Pharmacology. 2020 Mar 4;11:148. https://doi.org/10.3389/fphar.2020.00148
13. Kayode OT, Bello JA, Oguntola JA, Kayode AA, Olukoya DK. The interplay between monosodium glutamate (MSG) consumption and metabolic disorders. Heliyon. 2023 Sep 1;9(9). https://doi.org/10.1016/j.heliyon.2023.e19675
14. Parthasarathy S. How safe is monosodium glutamate? Exploring the link to obesity, metabolic disorders, and inflammatory disease. Journal of Medicinal Food. 2024 Dec;27(12):1259-.https://doi.org/10.1089/jmf.2014.1705.ed
15. Sankar J, Chauhan A, Singh R, Mahajan D. Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. Frontiers in Pharmacology. 2024 Sep 19;15:1441147. https://doi.org/10.3389/fphar.2024.1441147
16. Ridahunlang N, Bisht R, Rishanlang N. Isoniazid derivatives as anti-tubercular agents: From structural design to clinical investigations. Infectious Disorders-Drug TargetsDisorders). 2023 May 1;23(3):44-68. https://doi.org/10.2174/1871526522666221004152324
17. Kuang W, Zhang H, Wang X, Yang P. Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis. Acta Pharmaceutica Sinica B. 2022 Aug 1;12(8):3201-14. https://doi.org/10.1016/j.apsb.2022.04.014
18. Chauhan M, Barot R, Yadav R, Joshi K, Mirza S, Chikhale R, Srivastava VK, Yadav MR, Murumkar PR. The Mycobacterium tuberculosis cell wall: an alluring drug target for developing newer anti‐TB drugs—a perspective. Chemical Biology & Drug Design. 2024 Sep;104(3):e14612. https://doi.org/10.1111/cbdd.14612
19. Lei S, Gu R, Ma X. Clinical perspectives of isoniazid-induced liver injury. Liver Research. 2021 Jun 1;5(2):45-52. https://doi.org/10.1016/j.livres.2021.02.001
20. Murugaiha JS. Micronutrient deficiency in pulmonary tuberculosis-perspective on hepatic drug metabolism and pharmacokinetic variability of first-line anti-tuberculosis drugs: special reference to fat-soluble vitamins A, D, & E and nutri-epigenetics. Drug Metabolism Letters. 2021 Nov 1;14(3):166-76. https://doi.org/10.2174/1872312814999211130093625
21. Ezhilarasan D. Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms. Drug metabolism reviews. 2023 Jul 3;55(3):239-53. https://doi.org/10.1080/03602532.2023.2215478
22. Goh ZH, Tee JK, Ho HK. An evaluation of the in vitro roles and mechanisms of Silibinin in reducing pyrazinamide-and isoniazid-induced hepatocellular damage. International Journal of Molecular Sciences. 2020 May 25;21(10):3714. https://doi.org/10.3390/ijms21103714
23. Mahajan R, Tyagi AK. Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis. BMC Genomic Data. 2024 Dec 5;25(1):103. https://doi.org/10.1186/s12863-024-01286-y
24. Zade D. Hepatotoxicity associated with anti-tuberculosis medications: analyzing mechanisms, risk factors, and strategies for prevention and management. Journal of Drug Delivery and Biotherapeutics. 2024 Dec 25;1(03):01-12. https://doi.org/10.61920/jddb.v1i03.155
25. Fan, Y., Liu, Y., Shao, C., Jiang, C., Wu, L., Xiao, J., & Tang, L. (2025). Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives. International journal of molecular sciences, 26(12), 5486. https://doi.org/10.3390/ijms26125486
26. Miller DM, McCauley KF, Dunham‐Snary KJ. Metabolic dysfunction‐associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinology, diabetes & metabolism. 2025 Nov;8(6):e70132. https://doi.org/10.1002/edm2.70132
27. Hammad S, Ogris C, Othman A, Erdoesi P, Schmidt-Heck W, Biermayer I, Helm B, Gao Y, Piorońska W, Holland CH, D’Alessandro LA. Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation. Cell death & disease. 2023 Jul 12;14(7):414. https://doi.org/10.1038/s41419-023-05855-4
28. Lim J, Kim JS, Kim HW, Kim YH, Jung SS, Kim JW, Oh JY, Lee H, Kim SK, Kim SH, Lyu J. Metabolic disorders are associated with drug-induced liver injury during antituberculosis treatment: a multicenter prospective observational cohort study in Korea. InOpen Forum Infectious Diseases 2023 Aug (Vol. 10, No. 8, p. ofad422). US: Oxford University Press. https://doi.org/10.1093/ofid/ofad422
29. Karaboduk H, Adiguzel C, Uzunhisarcikli M, Apaydin FG, Kalender Y. Melatonin mitigates abamectin‐induced subacute hematotoxicity and hepato‐renal toxicity in rats by regulating oxidative stress, inflammatory responses, and apoptosis. Journal of Biochemical and Molecular Toxicology. 2025 Oct;39(10):e70512. https://doi.org/10.1002/jbt.70512
30. Anapana G, Vakita VR. Azoxystrobin-induced behavioural and physiological toxicity in grass carp (Ctenopharyngodon idella): Ecological implications for aquaculture environments. Journal of Chemical Health Risks. 2025. https://doi.org/10.60829/jchr.2025.1206586
31. Onuma K, Watanabe M, Sasaki N. The grimace scale: a useful tool for assessing pain in laboratory animals. Experimental Animals. 2024;73(3):234-45. https://doi.org/10.1538/expanim.24-0010
32. Mejía-Guzmán JE, Belmont-Hernández RA, Chávez-Tapia NC, Uribe M, Nuño-Lámbarri N. Metabolic-dysfunction-associated steatotic liver disease: molecular mechanisms, clinical implications, and emerging therapeutic strategies. International Journal of Molecular Sciences. 2025 Mar 25;26(7):2959. https://doi.org/10.3390/ijms26072959
33. Tong Y, Xu S, Huang L, Chen C. Obesity and insulin resistance: Pathophysiology and treatment. Drug discovery today. 2022 Mar 1;27(3):822-30. https://doi.org/10.1016/j.drudis.2021.11.001
34. Kermanizadeh A, Valli J, Sanchez K, Hutter S, Pawlowska A, Whyte G, Moritz W, Stone V. Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH. Archives of toxicology. 2022 Jan;96(1):287-303. https://doi.org/10.1007/s00204-021-03181-2
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Baseerat Naz, Ambar Shaheen, Sadia, Aqila Azam
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
